AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

Company Leadership Transition - Azenta, Inc. announced the appointment of John P. Marotta as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring after 14 years [1][3] - Dr. Schwartz will remain as an advisor to ensure a smooth transition [1] Executive Background - Mr. Marotta has over 20 years of experience in leading global companies in life sciences, medical devices, and diagnostics, previously serving as CEO and President of PHC Holdings Corporation [2] - He has held senior executive roles at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health, demonstrating a track record of organic revenue growth and operational efficiencies [2] Board's Confidence - Frank E. Casal, Chairman of the Azenta Board, expressed confidence in Mr. Marotta's ability to lead the company into its next chapter, highlighting his extensive experience in high-growth life sciences businesses [3] - Mr. Marotta expressed excitement about joining Azenta and emphasized the company's strong foundation and growth opportunities [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services for drug development, clinical research, and advanced cell therapies [4] - The company operates globally with a presence in North America, Europe, and Asia, supporting top pharmaceutical, biotech, academic, and healthcare institutions [4]